BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24006289)

  • 1. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
    Truong M; Slezak JA; Lin CP; Iremashvili V; Sado M; Razmaria AA; Leverson G; Soloway MS; Eggener SE; Abel EJ; Downs TM; Jarrard DF
    Cancer; 2013 Nov; 119(22):3992-4002. PubMed ID: 24006289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
    Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
    World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients.
    Wang JY; Zhu Y; Wang CF; Zhang SL; Dai B; Ye DW
    Chin J Cancer; 2014 May; 33(5):241-8. PubMed ID: 24559852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
    Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.
    Chun FK; Steuber T; Erbersdobler A; Currlin E; Walz J; Schlomm T; Haese A; Heinzer H; McCormack M; Huland H; Graefen M; Karakiewicz PI
    Eur Urol; 2006 May; 49(5):820-6. PubMed ID: 16439050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
    Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
    Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.
    Seisen T; Roudot-Thoraval F; Bosset PO; Beaugerie A; Allory Y; Vordos D; Abbou CC; De La Taille A; Salomon L
    World J Urol; 2015 Jun; 33(6):787-92. PubMed ID: 24985552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology among Japanese patients.
    Imamoto T; Suzuki H; Utsumi T; Takano M; Suyama T; Kawamura K; Kamiya N; Naya Y; Ueda T; Ichikawa T
    Urology; 2010 Aug; 76(2):404-10. PubMed ID: 19716590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
    Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI
    BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gleason sum upgrading between biopsy and radical prostatectomy in Chinese population: Updated nomograms.
    Xu H; Bai PD; Hu MB; Mao SH; Zhu WH; Hu JM; Liu SH; Yang T; Hou JY; Hu Y; Ding Q; Jiang HW
    Actas Urol Esp; 2017 Apr; 41(3):162-171. PubMed ID: 27522521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy.
    Kim TH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Scand J Urol; 2017 Feb; 51(1):27-32. PubMed ID: 28168924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating association of perineural invasion on prostate biopsy with Gleason score upgrading at prostatectomy: A multi-institutional analysis.
    Barsky AR; Kraus RD; Carmona R; Santos PMG; Li C; Schwartz LE; Ballas LK; Vapiwala N
    Cancer Med; 2020 May; 9(10):3383-3389. PubMed ID: 32187859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
    Coley RY; Zeger SL; Mamawala M; Pienta KJ; Carter HB
    Eur Urol; 2017 Jul; 72(1):135-141. PubMed ID: 27523594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
    Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.